Evidence map›Paper›PMID 36068547›Full record

ArticleTrials2022

Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.

Guangyi Gao, Byron J Gajewski, Jo Wick, Jonathan Beall, Jeffrey L Saver, Caitlyn Meinzer, STEP-STONE Executive Committee

Abstract read
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guangyi GaoDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, 66160, USA. ggao1991@gmail.com.ORCID http://orcid.org/0000-0003-3050-726X
Byron J GajewskiDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Jo WickDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Jonathan BeallDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA.
Jeffrey L SaverDepartment of Neurology and Comprehensive Stroke Center, University of California, Los Angeles, CA, 90095, USA.
Caitlyn MeinzerDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA.
STEP-STONE Executive Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatform trials are well-known for their ability to investigate multiple arms on heterogeneous patient populations and their flexibility to add/drop treatment arms due to efficacy/lack of efficacy. Because of their complexity, it is important to develop highly optimized, transparent, and rigorous designs that are cost-efficient, offer high statistical power, maximize patient benefit, and are robust to changes over time.

methodsTo address these needs, we present a Bayesian platform trial design based on a beta-binomial model for binary outcomes that uses three key strategies: (1) hierarchical modeling of subgroups within treatment arms that allows for borrowing of information across subgroups, (2) utilization of response-adaptive randomization (RAR) schemes that seek a tradeoff between statistical power and patient benefit, and (3) adjustment for potential drift over time. Motivated by a proposed clinical trial that aims to find the appropriate treatment for different subgroup populations of ischemic stroke patients, extensive simulation studies were performed to validate the approach, compare different allocation rules, and study the model operating characteristics. RESULTS AND

conclusionsOur proposed approach achieved high statistical power and good patient benefit and was also robust against population drift over time. Our design provided a good balance between the strengths of both the traditional RAR scheme and fixed 1:1 allocation and may be a promising choice for dichotomous outcomes trials investigating multiple subgroups.

Indexed as

Clinical Trials as TopicResearch DesignStrokeAdaptive Clinical Trials as TopicBayes TheoremComputer SimulationHumansModels, StatisticalRandom AllocationBayesian modelsBeta-binomialHierarchical modelsPlatform trial designResponse-adaptive randomization

Identifiers

PMID36068547
PMCPMC9446515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.